Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
The primary endpoint is to measure the change in liver stiffness measurement performed by transient elastography from Baseline to Week 52
Records revenue growth of 22% to Rs. 762 crores in Q4 FY23 and grew 30% to Rs. 3149 crores in FY23
Olverembatinib is the first and only third-generation BCR-ABL inhibitor approved in China for the treatment of adult patients with tyrosine kinase inhibitors
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Lucid-MS is a new drug candidate for the treatment of multiple sclerosis
‘Fibrotic disease’ is a term that covers a range of diseases characterized by uncontrolled and progressive fibrosis,
Proposed divestiture of BioPharma Solutions (BPS) further streamlines Baxter’s strategic focus and represents an important milestone in its ongoing business transformation
The Research by Indian Fellow at the University has major implications for neurodegenerative disease treatments
Subscribe To Our Newsletter & Stay Updated
